46 AVENUE DE LA GRANDE ARMEE, PARIS, I0
Market cap: $116.2B (2/05/2026)
Price: $47.83
Announces the Signing of a Share Buyback Mandate for Up to €1 Billion
Strong Sales and EPS Growth. Continued Profitable Growth Expected in 2026
Amlitelimab confirms its potential in atopic dermatitis
Myqorzo and Redemplo approved
Tzield Accepted for Priority Review in the US for Young Children with Stage 2 Type 1 Diabetes
To acquire, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline
Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia
Provides Update on Tolebrutinib Regulatory Submission in Non-Relapsing Secondary Progressive Multiple Sclerosis
Annual and Transition Report of Foreign Private Issuers
Amended Annual and Transition Report of Foreign Private Issuers
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Additional Information Statement
Contested Proxy Solicitation Materials
PRRN14A
Amended Schedule 13G - Ownership Report
Quarterly Holdings Report for Institutional Managers
Annual Report of Proxy Voting Record
Annual Report of Employee Stock Purchase
S-8 POS
Amended Tender Offer Statement by Third Party
Free Writing Prospectus